
The approval of lenacapavir for use as pre-exposure prophylaxis is a significant step in reducing the incidence of HIV across the globe, including in areas where the PURPOSE trials were conducted.

Associate Professor of Medicine (AIDS) and of Pharmacology, Yale
Principal investigator, PURPOSE 2

The approval of lenacapavir for use as pre-exposure prophylaxis is a significant step in reducing the incidence of HIV across the globe, including in areas where the PURPOSE trials were conducted.

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512
© 2025 MJH Life Sciences®
All rights reserved.
